NCT02733289

Brief Summary

Standard evaluation and follow-up data regarding complications of curative radiation treatment for cervical cancer.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
178mo left

Started Jun 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Jun 2015Dec 2040

Study Start

First participant enrolled

June 1, 2015

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

March 17, 2016

Completed
25 days until next milestone

First Posted

Study publicly available on registry

April 11, 2016

Completed
24.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2040

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2040

Last Updated

February 28, 2024

Status Verified

February 1, 2024

Enrollment Period

25.5 years

First QC Date

March 17, 2016

Last Update Submit

February 26, 2024

Conditions

Cervical Cancer Radiation Complications

Outcome Measures

Primary Outcomes (1)

  • Complications

    Physiological parameters, questionnaires

    Five years

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Every patient who receives curative radiotherapy for cervical cancer at the department of Radiotherapy at the UMCG.

You may qualify if:

  • Every cervical cancer patient with curative intent for radiotherapy, treated at our department

You may not qualify if:

  • Non-curative treatment
  • Part of the treatment is given in another hospital

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Groningen

Groningen, Netherlands

RECRUITING

Study Officials

  • Jannet Beukema

    Principal Investigator

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jannet Beukema

CONTACT

+31503610025j.c.beukema@umcg.nl

Petra Veldhuijzen van Zanten

CONTACT

+31503614659p.veldhuijzen@umcg.nl

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2016

First Posted

April 11, 2016

Study Start

June 1, 2015

Primary Completion (Estimated)

December 1, 2040

Study Completion (Estimated)

December 1, 2040

Last Updated

February 28, 2024

Record last verified: 2024-02

Locations

NL(1)